JP2025506454A - Ｎ－｛［（ｓ）－｛［３－（４－クロロフェニル）－４－フェニル－４，５－ジヒドロ－１ｈ－ピラゾール－１－イル］［４－（トリフルオロメチル）ベンゼンスルホンアミド］メチリデン｝アミノ］メタンイミドイル｝アセトアミドの結晶形態 - Google Patents

Ｎ－｛［（ｓ）－｛［３－（４－クロロフェニル）－４－フェニル－４，５－ジヒドロ－１ｈ－ピラゾール－１－イル］［４－（トリフルオロメチル）ベンゼンスルホンアミド］メチリデン｝アミノ］メタンイミドイル｝アセトアミドの結晶形態 Download PDF

Info

Publication number
JP2025506454A
JP2025506454A JP2024547103A JP2024547103A JP2025506454A JP 2025506454 A JP2025506454 A JP 2025506454A JP 2024547103 A JP2024547103 A JP 2024547103A JP 2024547103 A JP2024547103 A JP 2024547103A JP 2025506454 A JP2025506454 A JP 2025506454A
Authority
JP
Japan
Prior art keywords
compound
temperature
degrees
formula
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547103A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506454A5 (https=
Inventor
デリック・マッカーシー
ミトゥルクマール・パテル
ジュン・ジョウ
チェン・チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of JP2025506454A publication Critical patent/JP2025506454A/ja
Publication of JP2025506454A5 publication Critical patent/JP2025506454A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024547103A 2022-02-09 2023-02-08 Ｎ－｛［（ｓ）－｛［３－（４－クロロフェニル）－４－フェニル－４，５－ジヒドロ－１ｈ－ピラゾール－１－イル］［４－（トリフルオロメチル）ベンゼンスルホンアミド］メチリデン｝アミノ］メタンイミドイル｝アセトアミドの結晶形態 Pending JP2025506454A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263267734P 2022-02-09 2022-02-09
US63/267,734 2022-02-09
PCT/CA2023/050163 WO2023150874A1 (en) 2022-02-09 2023-02-08 Crystalline forms of n-{[(s)-{[3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1h-pyrazol-1-yl][4-(trifluoromethyl)benzene sulfonamido]methylidene}amino] methanimidoyl}acetamide

Publications (2)

Publication Number Publication Date
JP2025506454A true JP2025506454A (ja) 2025-03-11
JP2025506454A5 JP2025506454A5 (https=) 2026-01-21

Family

ID=87563337

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547103A Pending JP2025506454A (ja) 2022-02-09 2023-02-08 Ｎ－｛［（ｓ）－｛［３－（４－クロロフェニル）－４－フェニル－４，５－ジヒドロ－１ｈ－ピラゾール－１－イル］［４－（トリフルオロメチル）ベンゼンスルホンアミド］メチリデン｝アミノ］メタンイミドイル｝アセトアミドの結晶形態

Country Status (5)

Country Link
US (1) US20250188038A1 (https=)
EP (1) EP4476200A4 (https=)
JP (1) JP2025506454A (https=)
CN (1) CN119032082A (https=)
WO (1) WO2023150874A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016196646A1 (en) * 2015-06-04 2016-12-08 The United States Of America, As Represented By The Secretary, Departmet Of Health & Human Services Cannabinoid receptor mediating compounds

Also Published As

Publication number Publication date
EP4476200A4 (en) 2026-01-14
EP4476200A1 (en) 2024-12-18
US20250188038A1 (en) 2025-06-12
WO2023150874A1 (en) 2023-08-17
CN119032082A (zh) 2024-11-26

Similar Documents

Publication Publication Date Title
AU2024227212A1 (en) A 7H-pyrrolo[2,3-d]pyrimidine JAK-inhibitor
TWI548630B (zh) １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN117164581A (zh) 一种kras抑制剂或其盐的多晶型物及其制剂制备
JP2007302658A (ja) イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法
CA3034606A1 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
CN102070618B (zh) 一种化合物及其晶体
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
JP7825636B2 (ja) （ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
JP2022031797A (ja) 置換５，６－ジヒドロ－６－フェニルベンゾ［ｆ］イソキノリン－２－アミン化合物の固体形態
WO2016000568A1 (zh) 一种治疗痛风的化合物
JP2003517011A (ja) レフルノミドの新規な製法及び新しい結晶形態
TW201040161A (en) Crystalline polymorphic form 631
JP2002526532A (ja) トラセミドの新規な結晶変態ｎ型
TW201245183A (en) Solid forms of (S)-2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl)propanoic acid
JP2018516946A (ja) ヒストン脱アセチル化阻害剤の結晶形態
WO2016155578A1 (zh) 达格列净的新晶型及其制备方法
TWI836379B (zh) 化合物的多晶型及其製備方法和應用
TWI834536B (zh) 結晶
US20250129042A1 (en) Crystalline forms of 3-(5-(2-hydroxy-2-methylpropoxy)-6-methylpyrazin-2-yl)-1h-indole-7-carbonitrile
WO2016188444A1 (zh) 一种尿酸转运蛋白抑制剂的钠盐及其结晶形式
JP2025506454A (ja) Ｎ－｛［（ｓ）－｛［３－（４－クロロフェニル）－４－フェニル－４，５－ジヒドロ－１ｈ－ピラゾール－１－イル］［４－（トリフルオロメチル）ベンゼンスルホンアミド］メチリデン｝アミノ］メタンイミドイル｝アセトアミドの結晶形態
TW201008935A (en) Crystalline forms of thiazolidinedione compound and its manufacturing method
EA006245B1 (ru) Гидрохлорид 4-[4-(2-пирролилкарбонил)-1-пиперазинил]-3-трифторметилбензоилгуанидина
TWI922665B (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
CN113999205B (zh) 含三氮唑酮酰胺和咪唑酰胺结构的吡啶类化合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260109